<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>Shahid Sadoughi University of Medical Sciences
https://en.ssu.ac.ir/publications/</PublisherName>
				<JournalTitle>Advances in Pharmacology and Therapeutics Journal</JournalTitle>
				<Issn>2783-3445</Issn>
				<Volume>5</Volume>
				<Issue>2</Issue>
				<PubDate PubStatus="epublish">
					<Year>2025</Year>
					<Month>09</Month>
					<Day>22</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Frontotemporal Dementia and the Therapeutic Void: Bridging the Gap in Drug Development for FTD</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>103</FirstPage>
			<LastPage>105</LastPage>
			<ELocationID EIdType="pii">440</ELocationID>
			
<ELocationID EIdType="doi">10.18502/aptj.v5i2.19459</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Mohsen</FirstName>
					<LastName>Zabihi</LastName>
<Affiliation></Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2025</Year>
					<Month>06</Month>
					<Day>22</Day>
				</PubDate>
			</History>
		<Abstract>Frontotemporal dementia (FTD) is a progressive and early-onset neurodegenerative condition, and there are no approved disease-modifying therapies. Despite growing insight into its molecular pathology and the development of biomarkers and genetic stratification tools, drug development for FTD remains limited. Significant challenges include the clinical and pathological heterogeneity of the disease, difficulties in early diagnosis, and limited commercial incentives due to its relative rarity. This editorial highlights the urgent need for coordinated translational research efforts, international collaboration, and robust funding mechanisms to accelerate therapeutic innovation. While the scientific groundwork is promising, overcoming the current therapeutic void requires sustained and strategic global initiatives.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Frontotemporal dementia</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">drug development</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">therapeutic gap</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">neurodegeneration</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Biomarkers</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">translational research</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">precision medicine</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://aptjournal.ssu.ac.ir/article_440_05df93c636df337483e96d7c86abcb0c.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
